Home > Historical Performance > Historical Transaction Report

Transaction Details

Company: Myriad Genetics
Ticker:MYGN
Yahoo Beta:0.28
Industry:Research services

Company Description:  Myriad Genetics offers a number of genetic tests that aid in personalized medicine.

Purchase Date:25 Jan 2017 Sale Date:19 Oct 2017
Purchase Price:$16.50 Sale Price:$34.51
  --Split Adjusted:$16.50  --Split Adjusted:$34.51
Shares Purchased:185 Shares Sold:185
  --Split Adjusted:185  --Split Adjusted:185
Transaction Fee:$6.95 Transaction Fee:$5.10
Price Range (6 Months Prior):    Price Range (6 Months After):    
High$31.48 High$0.00
Date01 Aug 2016 Date01 Jan 1996
Low$15.46 Low$0.00
Date19 Jan 2017 Date01 Jan 1996
S&P (Purchase Date):$2,294.09 S&P (Sale Date):$2,562.10

Purchase
Timing:  We bought near the six month low.
Reason:  Myriad's stock dropped significantly after it lost a court case that resulted in generic competition for its most significant test. Our analysts believe that the market has not priced in the recent acquisition of Assurex and its Genesight product. We view Myriad as a turnaround story. The company maintains a strong position with a solid reputation for lab accuracy, a proprietary database, and a diversified portfolio of products. We anticipate that Myriad's price may be volatile over the next year as its products come to market, but believe it is a strong long-term buy.

Sale
Timing:  0
Reason:  Myriad Genetics has been experiencing a decline in sales in its historically strong area of hereditary test kits. The company has been losing market share. Our analyst believes its latest product, GeneSight, is now overvalued.

S&P Gain: 11.68 % Annualized Gain: 16.3%
Stock Gain: 109.15 % Annualized Gain: 174.21%

Dividends:$0.00
Net Holding Return ($): $3,319.80
Net Holding Return (%): 108.51 %